These results suggest that BAF60a promotes AAA formation by facilitating inflammation and ECM degradation, and therefore, BAF60a may serve as a potential target for the prevention and treatment of AAA (Chang et al., 2020) (Figure 3). The gene discussed is SMARCD1; the disease is triple-A syndrome.